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Abstract
Identification of individuals who are at risk of suffering from acute coronary syndromes
(ACS) may allow to introduce preventative measures. We aimed to identify ACS-related uri-
nary peptides, that combined as a pattern can be used as prognostic biomarker. Proteomic
data of 252 individuals enrolled in four prospective studies from Australia, Europe and North
America were analyzed. 126 of these had suffered from ACS within a period of up to 5 years
post urine sampling (cases). Proteomic analysis of 84 cases and 84 matched controls
resulted in the discovery of 75 ACS-related urinary peptides. Combining these to a peptide
pattern, we established a prognostic biomarker named Acute Coronary Syndrome Predictor
75 (ACSP75). ACSP75 demonstrated reasonable prognostic discrimination (c-statistic =
0.664), which was similar to Framingham risk scoring (c-statistics = 0.644) in a validation
cohort of 42 cases and 42 controls. However, generating by a composite algorithm named
Acute Coronary Syndrome Composite Predictor (ACSCP), combining the biomarker pattern
ACSP75 with the previously established urinary proteomic biomarker CAD238 characteriz-
ing coronary artery disease as the underlying aetiology, and age as a risk factor, further
improved discrimination (c-statistic = 0.751) resulting in an added prognostic value over Fra-
mingham risk scoring expressed by an integrated discrimination improvement of 0.273 ±
0.048 (P < 0.0001) and net reclassification improvement of 0.405 ± 0.113 (P = 0.0007). In
conclusion, we demonstrate that urinary peptide biomarkers have the potential to predict
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future ACS events in asymptomatic patients. Further large scale studies are warranted to
determine the role of urinary biomarkers in clinical practice.
Introduction
Coronary artery disease (CAD) and its complications such as acute coronary syndrome (ACS)
are a leading cause of morbidity and mortality worldwide [1]. Several directions have been
taken to search for the ideal methods for predicting future cardiovascular events, including
simple clinical risk scoring systems such as the Framingham Risk Score and non-invasive tech-
niques such as carotid intima-media thickness measurements by ultrasound. Novel alternative
approaches have also been investigated, for example, fundus photography to measure retinal
vessel calibers with narrower retinal arterioles and wider retinal venules conferring a greater
risk of death, stroke and coronary artery disease in women [2]. The biomarker approach is one
of the rapidly expanding areas in this field, starting from more traditional high density lipopro-
tein (HDL) cholesterol to high-sensitivity C-reactive protein (hsCRP), N-terminal pro-brain
natriuretic peptide P (NT-proBNP), or even microparticles and microRNAs [3,4]. Reliable bio-
markers to predict future ACS-events could lead to improved risk stratification, enable earlier
interventions and potentially reduce the incidence of ACS. Current attempts include single
biomarkers as well as biomarker combinations directed towards prediction of ACS specially or
to CAD in general [5,6]. Yin et al. used mass spectrometry based plasma proteomics to identify
protein biomarkers for the new onset of acute myocardial infarction (AMI) during a 3-year
follow up in the Framingham Heart Study offspring cohort [5]. A multi-marker model com-
posed of seven plasma proteins thereby reached a median C-statistic of 0.84 and exceeded
models with regular clinical covariates.
Although this approach represents a first step towards predicting ACS, particularly AMI,
based on proteomic biomarkers, routine blood proteomics can be challenging. This is due to
the influence of processing, handling and storage of the specimen, and the potential instabili-
ties of the proteome. We therefore used urine proteome analysis (UPA) for the identification
of prognostic biomarkers for ACS. Proteome analysis of urine has been shown to be a rich and
stable source of specific pathology-related information for multiple conditions including car-
diovascular and renal diseases, revealing diagnostic and, more importantly, prognostic rele-
vance [7–12]. It has been shown that UPA identified patients with coronary artery disease
(CAD) using a diagnostic disease biomarker based on a 238 urinary peptide pattern CAD238
[7]. CAD238 also revealed a prognostic potential for CAD endpoints including non-fatal AMI
[12]. In the current multi-cohort study, we explored the urinary proteome profiles of partici-
pants from Australian, European and North American prospective cohorts to identify an
ACS-specific pattern of urinary peptides that will allow prediction of future ACS events.
Methods
Study population
This study drew cases, comprising individuals with an ACS within 5 years post urine sampling
with available urinary proteomic data, and sex- and age-matched controls without ACS from
four separate studies conducted in Australia, Europe and North America. In total 218 proteo-
mic data sets (109 incident ACS cases and 109 controls without ACS during follow-up) origi-
nated from the Australian Diabetes, Obesity and Lifestyle (AusDiab) study which is the largest
Australian longitudinal population-based study examining the natural history of diabetes,
Urine proteomics to predict ACS
PLOS ONE | DOI:10.1371/journal.pone.0172036 March 8, 2017 2 / 18
Wetenschappelijk Onderzoek Vlaanderen, Ministry
of the Flemish Community, Brussels, Belgium
(G.0881.13 and G.0880.13) supported the
FLEMENGHO study. N. M. Htun was supported by
scholarships from the Cardiac Society of Australia
and New Zealand (CSANZ) and NHMRC, Australia.
D. J. Magliano, J. E. Shaw and K. Peter are
supported by research fellowships from the
NHMRC. The funders provided support in the form
of salaries for authors [NMH, DJM, ENK, JPS, CD,
HM, JAS, JES, TK, KP], but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of these authors
are articulated in the ‘author contributions’ section.
Competing interests: The authors have declared
the following potential conflict of interest: H.
Mischak is the founder and coowner of Mosaiques
Diagnostics GmbH, who developed the CE-MS
technology for clinical application. E. Nkuipou-
Kenfack, A. Ramirez-Torres, C. Pontillo, M.
Pejchinovski and T. Koeck are employees of
Mosaiques Diagnostics GmbH. This does not alter
our adherence to PLOS ONE policies on sharing
data and materials.
heart disease and kidney disease [13]. Fourteen proteome profile data sets (7 ACS cases and 7
controls without ACS during follow-up) originated from the Flemish Study on Environment,
Genes and Health Outcomes (FLEMENGHO) which is a prospective population-based study
examining the potential effects of specific genes on blood pressure conducted in Northern Bel-
gium [8,9]. Eight proteome profile data sets (4 ACS cases and 4 controls without ACS during
follow-up) originated from the Coronary Artery Calcification in Type 1 Diabetes Study
(CACTI) which is a longitudinal cohort study investigating the determinants of atherosclerosis
in people with and without type 1 diabetes [14]. Twelve proteome profile data sets (6 ACS
cases and 6 controls without ACS during follow-up) originated from the Hypertensive Athero-
sclerotic Cardiovascular Disease (HACVD) sub-study population of the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) study [12]. The study was conducted in accordance with
the principles of the Declaration of Helsinki and written informed consent was obtained from
all the participants. The study was approved by the local ethics committee at the Medical
School Hannover, approval number 3184–2016.
All participants were asymptomatic of coronary artery disease at the time of enrolment
when urine samples were collected. Cardiovascular outcomes were adjudicated up to 5 years
post urine sampling (see assessment of outcome section). The study population was split ran-
domly into 2 groups (biomarker discovery cohort and validation cohort) by a to ratio. The
biomarker discovery cohort was used to identify urinary peptide biomarkers which might
potentially discriminate cases (individuals with future ACS events during follow-up) from
controls (individuals without ACS during follow-up). 84 cases with 84 age- (within 5 years)
and sex-matched controls were randomly selected for this purpose. The urinary peptide bio-
markers thus identified were then applied to the remainder of the cases and controls for
validation (validation cohort) in a blinded manner. 42 cases and 42 controls were used for vali-
dation. Thirty-six (28.6%) out of the 126 participants with an ACS event during the observa-
tion period of 5 years (cases) had a previous history of angina pectoris and/or AMI. In the
other 90 participants it was the first cardiac event without a past history of known coronary
artery disease. Out of the 126 control individuals 9 (8.3%) had previous angina pectoris and/or
AMI but had no ACS event during the observation period.
Assessment of outcome
For this study four outcomes were considered, non-fatal ACS (N = 67), fatal ACS (N = 58),
ACS without information on fatality (N = 1) and no ACS during a follow-up time up to 5 years
after urine sampling (controls). Non-fatal ACS was defined as either non-fatal AMI or new
onset or worsening angina pectoris requiring hospitalization with angiographically docu-
mented coronary atherosclerosis or transient electrocardiographic changes of the ST-segment
or T-wave without evidence for myocardial necrosis. AMI was defined as having at least two
of: (i) a typical clinical presentation, (ii) ECG changes and (iii) cardiac enzymes rises (includ-
ing creatine kinase and troponin) compliant with World Health Organisation MONICA crite-
ria for myocardial infarction. Fatal ACS was defined from death certificate coding, using
International Classification of Diseases Version 10 (ICD-10) codes I20-I25.
Sample preparation and Capillary Electrophoresis–Mass Spectrometry
(CE-MS) analysis
Urine sampling followed established standard operating procedures. Samples were kept frozen
at -80˚C, which has been shown to preserve proteomic profiles [15]. Proteomic analysis of all
urine samples was performed by Mosaiques Diagnostics using the same protocol for all cohorts
investigated. For proteomic analysis, 0.7 mL aliquot of urine was thawed immediately before
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use and diluted with 0.7 mL of 2 M urea, 10 mM NH4OH containing 0.02% sodium dodecyl
sulfate. To remove higher molecular mass proteins, such as albumin and immunoglobulin
G, the sample was ultra-filtered using Centrisart ultracentrifugation filter devices (20 kDa
MWCO; Sartorius, Goettingen, Germany) at 3000 rcf until 1.1 ml of filtrate was obtained. This
filtrate was then applied onto a PD-10 desalting column (GE Healthcare, Uppsala, Sweden)
equilibrated in 0.01% NH4OH in HPLC-grade in H2O (Roth, Germany) to decrease matrix
effects by removing urea, electrolytes, salts, and to enrich polypeptides present. Finally, all
samples were lyophilized, stored at 4˚C, and suspended in HPLC-grade H2O shortly before
CE-MS analyses, as described previously [16].
CE-MS analyses were performed using a P/ACE MDQ capillary electrophoresis system
(Beckman Coulter, Fullerton, USA) on-line coupled to a microTOF MS (Bruker Daltonics,
Bremen, Germany) as described previously [16,17]. The ESI sprayer (Agilent Technologies,
Palo Alto, CA, USA) was grounded, and the ion spray interface potential was set between –4
and –4.5 kV. Data acquisition and MS acquisition methods were automatically controlled by
the CE via contact-close-relays. Spectra were accumulated every 3 s, over a range of m/z 350 to
3000. Accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS
measurements were demonstrated elsewhere [16].
Proteomics data processing
Mass spectral peaks representing identical molecules at different charge states were deconvo-
luted into single masses using MosaiquesVisu software [18]. Only signals with z>1 observed
in a minimum of 3 consecutive spectra with a signal-to-noise ratio of at least 4 were consid-
ered. Reference signals of 1770 urinary polypeptides were used for CE-time calibration by
locally weighted regression. For normalization of analytical and urine dilution variances, signal
intensities were normalized relative to 29 ‘‘housekeeping” peptides with small relative stan-
dard. For calibration, linear regression was performed [16,19]. Deviation of CE migration time
was controlled to be below 0.35 minutes after calibration. The resulting peak list characterized
each peptide by its molecular mass (Da) and normalized CE migration time (minutes). Nor-
malized signal intensity was used as a measure for relative abundance. All detected peptides
were deposited, matched, and annotated in a Microsoft SQL database allowing further statisti-
cal analysis [20]. For clustering, peptides in different samples were considered identical if mass
deviation was <50 ppm. Due to analyte diffusion effects, CE peak widths increase with CE
migration time. In the data clustering process, this effect was considered by linearly increasing
cluster widths over the entire electropherogram (19–45 min) from 2 to 5%.
Sequencing of polypeptides
Identified prognostic biomarkers for ACS events were in silico assigned to the previously
sequenced peptides from the Human urinary proteome database, version 2.0. Peptides from
the Human urinary proteome database were sequenced as described elsewhere [21,22].
Biomarker discovery
Peptides (< 20 kDa) present in urine as a result of naturally occurring protein degradation
were investigated as potential biomarkers. For this investigation, statistical analysis of selected
urinary proteome profiles was performed using non-parametric Wilcoxon rank sum test. Up to
2042 distinct peptides were analyzed in individual proteome profiles. Only peptides that were
present at a frequency of 70% or higher in either case or control group were considered as
potential biomarkers. Thus, the identified peptide biomarkers were independent of the cohort
and potential population-specific genetic variability. The false discovery rate adjustments of
Urine proteomics to predict ACS
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Benjamini-Hochberg [23] were employed to correct for multiple testing. A P-value less than
0.05 was considered to be statistically significant.
In each of the 4 study cohorts, participants with verified ACS during follow-up were ran-
domly assigned either to biomarker discovery or validation by a to ratio. The participants
selected for biomarker discovery were representative of the cases in each cohort and matched
to controls by age (within 5 years range) and sex. A match for cardiovascular (CV) risk based
on 10-year cardiovascular disease risk prediction scores generated by the primary lipid Fra-
mingham model [24] between cases and controls was intended but not always possible
(Table 1).
Support vector machine (SVM) modelling
The classifier established by SVM modelling allows the classification of samples in the high
dimensional data space. ACS-specific peptide biomarkers were combined into a single sum-
mary multidimensional classifier using the SVM-based MosaCluster proprietary software, ver-
sion 1.7.0 [25]. Classification is performed by determining the Euclidian distance (defined as
the SVM classification score) of the vector to a maximal margin separating hyperplane. The
SVM classifier uses the log2 transformed intensities of x features (peptides) as coordinates in
an N-dimensional space (N = 75 for the ACSP75 biomarker pattern). It then builds an N-1
dimensional hyperplane that spans this space by performing a quadratic programming optimi-
zation of a Lagrangian using the training labels only while allowing for samples to lie on the
wrong side of the plane. For such mistakes in classification the SVM introduces a cost parame-
ter C. Because non-separable problems in low dimensions may be separable in higher dimen-
sions the SVM uses the Kernel-trick to transform the samples to a higher dimensional space.
MosaCluster uses the standard radial basis functions as kernel. These functions are just Gaus-
sians with the parameter γ controlling their width. The optimal parameters C and γ are found
via e.g. cross validation error estimation using a lattice build by different values of these two
Table 1. Demographics and clinical features of the discovery cohort.
control (N = 84) ACS (N = 84)
Women (%) 36 35
Age, years 64 ± 11 64 ± 12
Systolic pressure (mm Hg) 136 ± 19 147 ± 23
Diastolic pressure (mm Hg) 72 ± 12 79 ± 13
BMI (kg/m2) 26 ± 4 29 ± 5
Current smokers (%) 10 24*
Total cholesterol (mmol/L) 6.0 ± 1.1 5.9 ± 1.3
HDL cholesterol (mmol/L) 1.5 ± 0.4 1.2 ± 0.3
eGFR (ml/min/1.73m2) 72 ± 11 70 ± 15
Diabetes mellitus (%) 13 29*
Hypertension (%) 45 69*
History of cardiac events (%)# 7 23*
Median time to event (years) N/A 2.3 ± 1.5
BMI, body mass index; HDL high-density lipoprotein cholesterol; diabetes mellitus type I and II; hypertension
was defined as blood pressure of140 mmHg systolic, or90 mm Hg diastolic, or use on antihypertensive
drugs; N/A, not available; some data (e.g. smoking status) are not available for all individuals)
# angina pectoris and/or AMI
Differences between cases and controls have been assessed by Mann-Whitney rank sum test and marked
with an * when P < 0.05.
doi:10.1371/journal.pone.0172036.t001
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parameters. SVMs are generally implemented in most popular data mining software, particu-
larly the kernlab cran contributed R package is a versatile tool for building SVM based-classifi-
ers [26].
Statistical methods and determination of predictive potential
For biomarker discovery, the reported unadjusted P-values were calculated using the univari-
ate non-parametric Wilcoxon rank sum test. Statistical adjustment due to the existence of
multiple test sets was performed by applying the Benjamini-Hochberg false discovery rate cor-
rections [27]. By maximizing Youden’s index based on exact binomial calculations carried out
in MedCalc version 12.7.3.0 (MedCalc Software, Mariakerke, Belgium, http://www.medcalc.
be), we determined optimal thresholds for the ACS classifier to differentiate individuals with
and without future ACS and calculated sensitivity and specificity given as mean along with
their 95% confidence intervals in brackets. We assessed the predictive capacity (discrimina-
tion) of models using Harrell’s c-statistic. The c-statistic estimates the probability of concor-
dance between predicted risk and the observed order of events from a randomly selected pair
of participants while accounting for censored data. A score of 1.0 indicates perfect discrimina-
tion and 0.5 indicates poor discrimination. The c-statistic and 95% confidence intervals (CI)
from each model were estimated using the somersd package, respectively, in STATA (version
12.1, (StataCorp, College Station, TX, USA), as described [28].
For demographic data, means were compared using ANOVA and proportions by Fisher’s
exact test. Statistical significance was a 1-sided significance level of 0.05.
We used Cox regression to compute standardized hazard ratios. The response variable used
was the “hazard” of an ACS occurring and baseline characteristics considered as covariates in
Cox regression were sex, age, current smoking status, body mass index, diabetes mellitus,
hypertension (office blood pressure of140 mmHg systolic, or90 mm Hg diastolic, use of
antihypertensive drugs and/or history of elevated blood pressure), estimated glomerular filtra-
tion rate (eGFR), total cholesterol, HDL cholesterol, and history of cardiovascular disease
(angina pectoris, myocardial infarction, stroke). We identified covariates to be retained in the
analyses by a step-down procedure, removing the least significant covariate at each step until
all P-values of covariates were less than 0.05. All Cox models complied with the proportional
hazards assumption.
To further evaluate the added predictive potential of the established prognostic algorithms
(ACSP75 and ACSCP), we used the net reclassification improvement (NRI) and the integrated
discrimination improvement (IDI) method [29]. We calculated the c-statistics, the NRI, and
IDI considering the risk categories <10% (low), 10–19% (intermediate), and20% (high) for
the 10-year cardiovascular disease risk prediction scores generated by the primary multi-
marker lipid Framingham model (FCVRS) [24]. The formulas for the calculation were as
follows:
(a) model 1: logit(y=ACS case/control) = α0 + α1 x [study centre] + α2 x [FCVRS]
(b) model 2: logit(y=ACS case/control) = α0 + α1 x [study centre] + α2 x [FCVRS] + α3 x
[ACSP75 score]
(c) model 3: logit(y=ACS case/control) = α0 + α1 x [study centre] + α2 x [FCVRS] + α3 x
[ACSCP score]
Results
Identification of biomarkers in the discovery data set
Proteomics data of all subjects involved in this study were listed in S1, S2, S3 and S4 Tables
(supporting information). To identify ACS-specific prognostic urinary peptide biomarkers
Urine proteomics to predict ACS
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potentially discriminating between individuals with (cases) and without (controls) future ACS
events, we compared the CE-MS-based urinary proteome profiles of 84 fatal and non-fatal
ACS cases occurring within a mean time interval of 2.34 ± 1.48 years during follow-up after
urine sampling and 84 age- and sex-matched controls. The clinical characteristics of these
selected cases and controls are presented in Table 1. The previously published proteomic bio-
marker pattern characteristic for coronary artery disease CAD238 [7,12] discriminated
between these patients and controls with a c-statistic of 0.574 (95% confidence interval)
(0.515–0.633) with adjustment for time to event. Classification by the 10-year cardiovascular
disease risk prediction scores generated by the composite multi-marker primary lipid Fra-
mingham model [24] resulted in a c-statistic of 0.636 (0.578–0.693) with adjustment for time
to event. The central assessment of the current study is the univariate analysis (including
correction for multiple testing) leading to the identification of 75 statistically significant
(P< 0.05) peptide biomarkers enabling the discrimination between cases and controls (Fig 1),
of which 54 (72%) were not part of the CAD238 biomarker pattern. 51 (68%) could be charac-
terized by sequence and post-translational modifications (Table 2). The majority of the
sequenced peptides originated from constituents of the extracellular matrix (ECM), i.e. frag-
ments of various types of collagens, comprising type I (N = 43) and II (N = 3), respectively.
Fig 1. Urinary polypeptide patterns of control and individuals with ACS. Panels A and B: Compiled polypeptide patterns of the
controls and individuals with ACS events during follow up after urine sampling examined in the training set; the molecular mass (0.6–
20 kDa, on a logarithmic scale) is plotted against normalized migration time (18–45 min). Signal intensity is encoded by peak height
and colour. Panels C and D: Distribution of potential biomarkers for ACS in controls and individuals with ACS events during follow up
after urine sampling based on the ACS-specific peptide biomarker pattern. All statistically significant biomarkers are shown.
doi:10.1371/journal.pone.0172036.g001
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Table 2. Sequenced peptides constituting the ACS-specific peptide panel and their differential excretion between ACS and Controls.
Peptide ID Protein name Accession number Sequence CAD 238 DE1
31525 Apolipoprotein A-IV P06727 FQDKLGEVNTY y
58084 Collagen alpha-1(I) chain P02452 GPpGPpGKNGDDGEAGKpG -1.35
90344 Collagen alpha-1(I) chain P02452 GKNGDDGEAGKpGRpGERGPpGPQ -1.04
23697 Collagen alpha-1(I) chain P02452 DDGEAGKpGRpG -1.07
82026 Collagen alpha-1(I) chain P02452 GNSGEpGApGSKGDTGAKGEpGPVG y -1.14
70635 Collagen alpha-1(I) chain P02452 NSGEpGApGSKGDTGAKGEpGP 1.06
79626 Collagen alpha-1(I) chain P02452 NSGEpGApGSKGDTGAkGEpGPVG y 1.04
72896 Collagen alpha-1(I) chain P02452 SGEpGApGSKGDTGAKGEpGPVG 1.12
5675 Collagen alpha-1(I) chain P02452 DGKTGPpGPA -1.27
28561 Collagen alpha-1(I) chain P02452 SpGPDGKTGPpGPA y -1.38
14906 Collagen alpha-1(I) chain P02452 DGRpGPpGPpG -1.27
127351 Collagen alpha-1(I) chain P02452 AAGEPGkAGERGVpGPpGAVGPAGKDGEAGAQGPPGP 1.00
49332 Collagen alpha-1(I) chain P02452 GPpGEAGKpGEQGVpGD 1.17
74902 Collagen alpha-1(I) chain P02452 GPpGEAGkPGEQGVPGDLGApGP -1.03
17694 Collagen alpha-1(I) chain P02452 ApGDRGEpGpP -1.12
32171 Collagen alpha-1(I) chain P02452 ApGDRGEpGPpGPA y -1.05
81758 Collagen alpha-1(I) chain P02452 ADGQpGAKGEpGDAGAKGDAGPpGP 1.00
85761 Collagen alpha-1(I) chain P02452 ADGQpGAKGEpGDAGAKGDAGPpGPA -1.06
77763 Collagen alpha-1(I) chain P02452 DGQpGAKGEpGDAGAKGDAGPPGp y 1.10
118224 Collagen alpha-1(I) chain P02452 ESGREGApGAEGSpGRDGSpGAKGDRGETGPA -1.06
78073 Collagen alpha-1(I) chain P02452 AEGSpGRDGSpGAKGDRGETGPA -1.40
43442 Collagen alpha-1(I) chain P02452 VGPpGPpGPpGPPGPPS 1.03
44618 Collagen alpha-1(I) chain P02452 VGPpGPpGPpGpPGPPS 1.01
34766 Collagen alpha-1(I) chain P02452 PpGPpGPpGpPGPPS -1.02
26113 Collagen alpha-2(I) chain P08123 GppGPDGNKGEpG 1.08
41431 Collagen alpha-1(II) chain P02458 GPpGKpGDDGEAGKPG y 1.02
27517 Collagen alpha-1(II) chain P02458 ApGEDGRpGPpGP 1.01
24502 Collagen alpha-1(II) chain P02458 GpVGpAGGpGFpGA
33973 Collagen alpha-1(II) chain P02458 PVGpSGKDGANGIpG -1.13
69769 Collagen alpha-1(III) chain P02461 DGESGRPGRpGERGLpGPpG 1.04
117770 Collagen alpha-1(III) chain P02461 GESGKPGANGLSGERGPPGpqGLpGLAGTAGEP
121716 Collagen alpha-1(III) chain P02461 GQPGVMGFpGPKGNDGAPGKNGERGGpGGpGpQ
70413 Collagen alpha-1(III) chain P02461 DGESGRpGRpGERGLpGPpG 1.00
61945 Collagen alpha-1(III) chain P02461 GLpGTGGPpGENGKpGEPGp 1.22
70911 Collagen alpha-1(III) chain P02461 GLpGTGGPpGENGKpGEPGpKG 1.12
18943 Collagen alpha-1(III) chain P02461 SpGERGETGPp -1.10
28747 Collagen alpha-1(III) chain P02461 SpGERGETGPpGP 1.25
84542 Collagen alpha-1(III) chain P02461 QNGEpGGKGERGAPGEKGEGGppG 1.01
71171 Collagen alpha-1(III) chain P02461 GEPGGkGERGApGEKGEGGpPG 1.24
141804 Collagen alpha-1(V) chain P20908 GEAGEPGLpGEGGpPGPKGERGEKGESGPSGAAGppGPKGP -1.02
56053 Collagen alpha-2(V) chain P05997 pGEGGKPGDqGVPGDPGAV y
102725 Collagen alpha-2(XI) chain P13942 GNEGpSGPPGpAGSPGERGAAGSGGPIGpPG 1.00
132834 Collagen alpha-1(XVI) chain Q07092 AGERGHPGAPGpSGSpGLPGVPGSMGDMVNYDEIK 1.29
42378 Collagen alpha-1(XVII) chain Q9UMD9 AmGpPGPPGAPGPAGPAG
99021 Collagen alpha-1(XXI) chain F5GZK2 KGDPGLPGNpGYpGqPGQDGKPGYQG y
40091 Collagen alpha-1(XXII) chain Q8NFW1 GpTGpPGKDGPnGPpG y
36156 Collagen alpha-1(XXV) chain Q9BXS0 KGDqGqAGPPGppGP y
(Continued )
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Other identified peptides originated from apolipoprotein A-IV, complement C3, fibrillin-1,
forkhead box protein O1, mucin-1, mucin-3, sarcalumenin or titin.
SVM modelling
The pattern of 75 ACS-specific peptide biomarkers was then applied to the urinary proteomic
profiles used for biomarker discovery in subsequent support vector machine (SVM) based
modelling of a proteomic prognostic ACS classifier. The resulting biomarker pattern Acute
Coronary Syndrome Predictor 75 (ACSP75; radial basis function kernel with parameters
C = 1638.4 and γ = 0.000256) allowed the classification of the ACS cases and controls of the
discovery cohort with a sensitivity (95% confidence interval) of 83.3% (73.6–90.6) and a speci-
ficity (95% confidence interval) of 96.4% (89.9–99.3).
Validation of the prognostic biomarker pattern ACSP75
The clinical characteristics of the study participants in the validation data set, comprising 42
individuals with future ACS events (cases; mean time-to-event 2.74 ± 1.51 years; maximum
time-to-event 4.89 years; Fig 2A) and 42 controls are presented in Table 3.
In comparison to controls, ACS cases were more likely to be older, hypertensive and have
diabetes as well as a history of cardiovascular events (HCVE). Analysis of the ACS scores gen-
erated from the urinary proteome profiles by the ACSP75 classifier showed that ACSP75 dis-
criminated between individuals with future ACS and controls with a sensitivity of 73.8%
(58.0–86.1) and a specificity of 73.8% (58.0–86.1) based on an optimized threshold value of
0.041 for the ACSP75 scores. This discriminatory power was further demonstrated by a c-sta-
tistic of 0.664 (0.587–0.741) with adjustment for time to event. The positive likelihood ratio
reached 2.82 (Fig 2B).
Table 2. (Continued)
Peptide ID Protein name Accession number Sequence CAD 238 DE1
108021 Complement C3 P01024 EGVQKEDIPPADLSDQVPDTESETR 1.23
52189 Fibrillin-1 H0YND0 ECVDTDECSVGNPCGN y -1.06
37056 Forkhead box protein O1 Q12778 SGQEGAGDSPGSQFS y
7094 Hemoglobin subunit beta P68871 SAVTALWGK 1.14
67263 Keratin; type II cytoskeletal 1 P04264 GSGGSSYGSGGGSYGSGGGGGGGRG -1.41
8342 Mucin-1 subunit alpha P15941 TTLASHSTK -1.09
45445 Mucin-3A Q02505 TSFSTIIWSSTPTI y 1.19
71312 Protocadherin-12 Q9NPG4 FAERNPVEELTVDSPPVQ 1.23
123750 Rhox homeobox family member 1 Q8NHV9 EGGVNHENGmNRDGGmIPEGGGGNQEPRQQ 1.16
69979 Sarcalumenin Q86TD4 EETEDANEEAPLRDRSH -1.19
31480 Titin Q8WZ42 KEADRGDSGTYD 1.08
65746 Uromodulin P07911 SGSVIDQSRVLNLGPITR -1.26
54438 Uromodulin P07911 VIDQSRVLNLGPITR 1.05
48176 Uromodulin P07911 IDQSRVLNLGPITR -1.07
Only peptides discriminatory for ACS and characterized by sequence are shown (N = 61). The differential excretion (DE) of peptides between ACS and
controls for the prognostic biomarker pattern ACSP75 has been calculated as follows: For mean MS amplitude (ACS) >mean MS amplitude (control):
(mean ampl. (ACS) x frequency) / (mean ampl. (control) x frequency); For mean MS amplitude (ACS) <mean MS amplitude (control):—(mean ampl.
(control) x frequency) / (mean ampl. (ACS) x frequency). For calculating means, values from all samples were used, considering 0 for undetected values;
Peptide ID, peptide identifier annotated by the SQL database; CAD238, also present in the biomarker pattern CAD238; P in peptide sequences, oxidized
prolines; m in peptide sequences, oxidized methionines.
doi:10.1371/journal.pone.0172036.t002
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Survival analysis for the biomarker pattern ACSP75
Longitudinal analysis of ACS events as outcomes in the validation cohort based on the prog-
nostic ACSP75 scores as a dichotomous variable (0 = ACSP75 scores 0.041; 1 = ACSP75
scores> 0.041) by the Kaplan-Meier method revealed an unadjusted hazard ratio of 4.39
(2.14–9.01) for individuals with an ACSP75 score above the threshold of 0.041 (Fig 2C). In
order to determine those clinical parameters relevant for ACS events as outcome/endpoint
(response variable) in addition to the prognostic ACSP75 score as a dichotomous variable, and
thus properly identify potential confounding factors, we performed stepwise Cox proportional
hazards regression analysis (backwards, removal P at> 0.1). Based on clinical characteristics
(Table 3), age, eGFR (estimated glomerular filtration rate), diabetes, hypertension and history
of cardiovascular events were selected as variables approximating to the rule of 1 independent
Fig 2. Performance of the ACSP75 urinary polypeptide classifier at follow up. A. Frequency histogram of ACS cases during follow-up. B. Receiver
operating characteristic (ROC) curve for the validation set (N = 168). ROC analyses for prediction of ACS using the urinary ACS biomarker pattern ACSP75
(blue solid line), urinary composite classification by ACSCP (red solid line) and Framingham risk score (FCVRS; black spotted line) are shown. C. Kaplan
Meier survival curve showing the cumulative percentage with an ACS event based on an ACSP75 score above (red solid line) and below (black spotted line)
the threshold of 0.041. D. Multi-variable adjusted Cox proportional-hazards regression analysis of the same data sets based on ACSP75 score above and
below the threshold of 0.041.
doi:10.1371/journal.pone.0172036.g002
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variable per 10 outcomes. The analysis revealed a variable-adjusted hazard ratio of 2.74 (1.32–
5.70; P = 0.0072) for ACSP75 (Fig 2D) and a c-statistic of 0.743 (0.660–0.827) with adjustment
for time to event. Finally, age and eGFR were identified as the only significant (P< 0.05) clini-
cal parameters showing a hazard ratio of 1.08 (1.03–1.13; P = 0.0017) and 0.97 (0.95–0.99;
P = 0.0098), respectively.
Comparison of biomarker pattern ACSP75 to the Framingham risk score
In comparison to urinary proteomic prognostic classification, a prognostic classification of
future ACS cases and controls in this study based on the well-recognized FCVRS model [24]
resulted in a c-statistic of 0.644 (0.547–0.741) (Fig 2B) with adjustment for time to event.
Thereby the common 20% high risk threshold for the Framingham score shows a sensitivity of
92.9% (80.5–98.5) but a specificity of only 31.0% (17.6–47.1). However, at the observed opti-
mized risk threshold of 41.5%, the sensitivity was 69.5% (52.9–82.4) and the specificity was
76.2% (60.5–87.9). A comparison of prognostic discriminatory power of FCVRS with ACSP75
showed no significant difference in c-statistic. Adding ACSP75 scores to FCVRS did not
provide any added prognostic value (Table 4; model 2 vs. 1) based on assessed incremental
improvement of integrated discrimination improvement (IDI) or net reclassification improve-
ment (NRI). Detailed formulas for the calculations for model 1 and 2 are provided in “Statisti-
cal methods and determination of predictive potential” section earlier.
Prognostic ACS classification by a composite score based on the
biomarker pattern ACSP75
To test if combining the ACSP75 scores with clinical patient parameters and other CAD-
related proteomic classifier scores further improves ACS prediction, we established the
ACSP75-based composite prognostic Acute Coronary Syndrome Composite Predictor
Table 3. Demographics and clinical features of the validation cohort.
control (N = 42) ACS (N = 42)
Women (%) 31 31
Age, years 68 ± 13 77 ± 9*
Systolic pressure (mm Hg) 147 ± 31 156 ± 22
Diastolic pressure (mm Hg) 78 ± 11 78 ± 13
BMI (kg/m2) 28 ± 4 27 ± 4
Current smokers (%) 2 7
Total cholesterol (mmol/L) 5.9 ± 1.6 5.9 ± 1.0
HDL cholesterol (mmol/L) 1.4 ± 0.3 1.4 ± 0.4
eGFR (ml/min/1.73m2) 72 ± 13 61 ± 17*
Diabetes mellitus (%) 19 43*
Hypertension (%) 69 95*
History of cardiac events (%) # 7 38*
Median time to event (years) N/A 2.7 ± 1.5
BMI, body mass index; HDL high-density lipoprotein cholesterol; diabetes mellitus includes type I and II;
hypertension was an office blood pressure of140 mmHg systolic, or90 mm Hg diastolic, or use of
antihypertensive drugs; eGFR, estimated glomerular filtration rate (MDRD formula); N/A, not available
# angina pectoris and/or AMI
Differences between cases and controls have been assessed by Mann-Whitney rank sum test and marked
with an * when P < 0.05; some data (e.g. smoking status) are not available for all individuals).
doi:10.1371/journal.pone.0172036.t003
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(ACSCP). It combined the ACSP75 biomarker pattern scores with age (see Cox analysis
above) as well as the CAD238 biomarker pattern scores specific for CAD [7,12] as parameters
significantly (P< 0.05) contributing to ACS prediction based on logistic regression analysis.
Other parameters like the eGFR showed no significant contribution. The formula for the cal-
culation of the prognostic ACSCP classification score based on logistic regression analysis was
as follows: ACSCP score = 0.2 x [ACSP75 score] + 2.6 x [CAD238 score] + 0.15 x [age]. When
classifying the study participants of the validation data set with ACSCP, it showed a c-statistic
of 0.751 (0.675–0.829) with adjustment for time to event with a sensitivity of 78.6% (63.2–89.7)
and a specificity of 92.9% (80.5–98.5) based on a threshold of 10.256. The c-statistic of ACSCP
was significantly higher than the one for the Framingham model (P = 0.021) showing a clear
advantage in prognostic discriminatory power for ACSCP (Fig 2B). To further evaluate an
added prognostic discriminatory power for ACSCP, we again assessed IDI and NRI (Table 4;
model 3 vs. 1) and observed a significant incremental improvement of IDI and NRI compared
to Framingham scoring. ACSCP therefore showed a positive likelihood ratio of 11.1. Detailed
formulas for the calculations for model 1 and 3 are provided in “Statistical methods and deter-
mination of predictive potential” section earlier.
Survival analysis for ACSCP
Longitudinal analysis of ACS events as outcomes in the validation cohort based on the prog-
nostic ACSCP scores as a dichotomous variable (0 = ACSCP score< 10.256; 1 = ACSCP
score > 10.256) by stepwise Cox proportional hazards regression analysis (backwards, removal
P at< 0.1) again adjusted for age, eGFR, diabetes, hypertension and history of cardiovascular
events revealed a variable-adjusted hazard ratio of 6.56 (2.36–18.25; P = 0.0003). None of the
clinical parameters showed a significant (P< 0.05) contribution.
Discussion
Peptides and some intact proteins circulating in the blood stream are excreted in urine
through variable filtration in the kidney. Since this had previously led to the identification of
urinary peptide biomarkers characteristic of atherosclerosis [30], particularly CAD [7,31,32],
we hypothesized that urinary proteome/peptidome profiles contain peptide biomarkers indic-
ative of different pathophysiological aspects in the progression of atherosclerotic plaques
towards the inflamed, unstable, “vulnerable”, thin-cap fibroatheromas that are prone to rup-
ture, and ultimately cause thrombotic occlusion of coronary arteries presenting as ACS. These
peptides might originate either from plaques themselves or from activated circulating cells
such as monocytes and platelets [33].
While prediction of ACS events in individuals of the discovery cohort using the already
established biomarker pattern CAD238 was ineffective, state-of-the-art CE-MS analyses of
Table 4. IDI and NRI for the prediction of ACS events by adding either ACSP75 or ACSCP scores to a
basal model based on Framingham 10-year cardiovascular disease risk prediction scores (FCVRS).
Model 2 vs. 1 Model 3 vs. 1
IDI 0.028 ± 0.015 0.284 ± 0.048
P-value IDI P = 0.0645 P < 0.0001
NRI 0.024 ± 0.024 0.405 ± 0.119
P-value NRI P = 0.3173 P = 0.0007
Model 2 vs. 1, improvement of basal FCVRS model (model 1) by adding ACSP75 scores; model 3 vs. 1,
improvement of model 1 by adding ACSCP scores.
doi:10.1371/journal.pone.0172036.t004
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their urinary proteome profile data allowed for the identification of ACS-specific urinary pep-
tide biomarkers and the establishment a new prognostic classifier based on these biomarkers.
This proteomic biomarker pattern ACSP75 proved to be capable of predicting the onset of an
ACS up to 4.89 years before the event with a sensitivity of 73.8% in individuals who were
asymptomatic at baseline. However, prediction of ACS with ACSCP surpassed prediction with
ACSP75 suggesting that optimal prediction of ACS events can be achieved by integrating a
urine peptide pattern characteristic for the presence of CAD and the age of an individual
[7,12].
The peptide biomarkers characterized so far by their amino acid sequence predominantly
originated from collagens, i.e. type I and III. Potential release of collagens via metalloprotei-
nase activity, which is known to be upregulated in unstable and inflamed plaques, has been
shown in human carotid endarterectomy specimens [34]. While surrounding endothelial cells
in the tunica intima, collagens also contribute to the composition of the three dimensional net-
work of vascular smooth muscle cells (VSMC), fibronectin, and proteoglycan-rich layers of the
tunica media as well as the composition of the fibroblast-rich tunica adventitia [35,36]. Type I
collagen can comprise approximately 60% of the total protein content of an atherosclerotic
plaque and plays, in addition to proteoglycans, an active role in lipid retention [37]. Both, type
I and III collagen are part of the complex and dynamic ECM of blood vessel walls thereby also
contributing to the strength and integrity of the fibrous cap of a plaque as well as the modula-
tion of cellular responses within it [35–37]. Moreover, a cap rich in fibrillar collagens and elas-
tin confers stability to the whole plaque. Initial accumulation of ECM, particularly collagens, is
further part of the fibrotic remodelling associated with hypertension and atherosclerosis
[38,39]. The observed decrease of collagen type I fragments and increase of type III fragments
in the excreted urine of individuals with a future ACS may therefore mirror atherogenic alter-
ations of the ECM that contribute to plaque destabilization along with a weakening of the
fibrous cap [37,40]. These processes may include altered collagen synthesis by endothelial cells
in the intima and/or fibroblast and myofibroblast cells in the adventitia layer of blood vessels
and therefore altered fibrillogenesis. They may also include altered covalent cross linking of
collagens by lysyl oxidases (LOX) and/or oxidative modification e.g. by reactive aldehydes
originating from oxidized low-density-lipoprotein [41] within the ECM. Collagens influence
the function and activity of cells in the arterial wall, i.e. VSMCs and macrophages [35,38]. The
composition of the ECM further directly regulates activities of proteases secreted by macro-
phages and VSMCs, which is highly relevant in the pathophysiology of plaque rupture [42].
The urinary biomarkers in our study seemed to be different from the plasma protein mak-
ers identified by Yin et al. A pattern of seven plasma proteins was found to be predictive of
AMI by Yin et al, which included cyclophilin A, cluster of differentiation 5 molecule antigen-
like cell-surface glycoprotein, mucin cell surface associated protein 18, collagen-α 1 [XVIII]
chain, salivary α-amylase 1, C-reactive protein (CRP) and multimerin-2 [5]. The reason for
this difference is not entirely clear although the urine proteome is expected to be inherently
different from the plasma proteome due to several factors including variable metabolism and
differential renal handling of some proteins and peptides. For example, CRP excretion in the
urine is rare [43] and despite being an established serum marker of CAD, has not been seen in
urine peptide patterns of CAD patients [7,31].
The previously described biomarker pattern CAD238 has been shown to be able to identify
patients with stable coronary artery disease, as validated in patients undergoing elective surgi-
cal coronary revascularization [7]. Brown et al found CAD238 can also be useful in predicting
the development of coronary artery disease in the future [12]. As the study cohort includes
patients with a broad spectrum of CAD (patients with fatal CAD, non-fatal MI as well as
patients just undergoing revascularization), it is not clear whether its prediction is specific for
Urine proteomics to predict ACS
PLOS ONE | DOI:10.1371/journal.pone.0172036 March 8, 2017 13 / 18
ACS or applies more broadly to coronary artery disease. Brown et al also found only some of
the markers in the CAD238 panel were different between cases and controls, and hypothesized
that these markers reflect earlier stages of CAD that had the potential to progress. It is interest-
ing to see there is some overlap of the urinary biomarkers identified in ACSP75 of our study
and the previously described CAD238 (Table 2). Some peptides derived from collagen alpha-1,
fibrillin-1, mucin-3A were found in both CAD238 and ACSP75. It is possible that CAD238
predominantly identifies the patients who have or might develop CAD. However when athero-
sclerotic plaques become relatively unstable, the urinary peptide pattern somewhat changes to
reflect the greater collagen breakdown in the fibrous cap, leaning towards ACSP75 pattern as
discussed earlier. This would explain some overlap between the two panels. ACSP75 alone
does not seem to perform better than the clinical Framingham score in predicting future car-
diovascular events, highlighting that clinical parameters are still very important. But combin-
ing these two patterns (CAD238 for the presence of atherosclerotic plaques and ACSP75 for
potential plaque instability) with age, which is the most important clinical risk factor in
ACSCP, significantly increases the predictive value for future ACS events.
Several of the peptides identified as biomarkers for ACS fit well in the mechanistic concept
of increased plaque instability in individuals with an increased risk of an ACS event. An associ-
ation with the pathogenesis of atherosclerosis has been shown for circulating complement C3
[44], and with acute myocardial infarction for titin [45] and fibrillin-1 [46]. Notably, some of
these proteins have also been identified in the urine of atherosclerotic mice [30], pointing out
the possibility that a mouse model for unstable plaques [47] can be used to further investigate
urinary biomarkers of plaque instability.
Our study adheres to the relevant guidelines of proteomic testing as the biomarkers de-
scribed have a clear context of use which is “prediction of ACS” and performance of the bio-
markers was not only evaluated in comparison to the current state of the art, but was also
validated in a separate cohort in a blinded fashion. The main limitation of our study is the
small sample size, especially in the validation cohort. While a positive discriminatory effect of
ACSCP even in a small study sample serves as a “proof of concept”, it should be validated in a
much larger independent cohort.
Conclusion
A newly established urinary biomarker pattern reflects molecular pathological alterations asso-
ciated with atherosclerotic plaque evolution towards “vulnerable” plaques, plaque rupture and
ultimately thrombotic artery occlusion. This biomarker pattern potentially allows for a suc-
cessful identification of individuals, who are at high risk of experiencing a future ACS event,
thereby enabling timely preventative interventions. Further prospective studies exploring
larger cohorts e.g. in the context of larger pharmacological trials are warranted to establish a
highly attractive non-invasive concept of identifying individuals at risk, with the potential
of initiating preventative measures and ultimately reducing cardiovascular mortality and
morbidity.
Supporting information
S1 Table. Cohort classification for biomarker discovery and validation. A total of 252 indi-
viduals were used in this study. 0 represents individuals with no Acute Coronary Syndrome
(ACS) used as controls and 1 represents individuals with ACS used as cases. For the biomarker
discovery, the discovery cohort was used and the validation cohort was used for the ACS classi-
fier validation.
(XLS)
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S2 Table. Mass spectrometry amplitudes of individuals. The amplitudes were given for all
252 individuals and all peptides (5605) identified by CE-MS.
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S3 Table. All identified peptides using CE-MS. For each peptide, mean CE-migration time
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